ストックスクリーナーアプリを入手
2.73
1.11%
0.03
前日終値:
$2.70
開ける：
$2.7
24時間の取引高:
159.02K
Relative Volume:
0.08
時価総額：
$46.55M
収益：
$3.86M
当期純損益:
$-14.44M
株価収益率:
-3.3787
EPS:
-0.808
ネットキャッシュフロー:
$-26.06M
1週間 パフォーマンス:
+17.17%
1か月 パフォーマンス:
+18.18%
6か月 パフォーマンス:
+19.21%
1年 パフォーマンス:
-26.42%
1日の値動き範囲:
$2.64
$2.7599
1週間の範囲:
$2.33
$2.89
52週間の値動き範囲:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Compare VERU vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.73 | 46.72M | 3.86M | -14.44M | -26.06M | -0.808 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-14 | 開始されました | B. Riley Securities | Buy |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2023-06-07 | アップグレード | Jefferies | Underperform → Hold |
| 2021-04-13 | 開始されました | Jefferies | Buy |
| 2021-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2018-07-03 | 開始されました | Maxim Group | Buy |
すべてを表示
Veru Inc (VERU) 最新ニュース
Veru 3Q Loss $6.99M >VERU - Moomoo
Veru Releases Q3 2026 Financial Results - AlphaStreet
Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances - Investing.com
VERU: PLATEAU trial enrollment completed, interim data due Q1 2027, and patent protection extended to 2044 - TradingView
VERU INC. 3Q 2026: Revenue $0 Net loss $6.99M, EPS ($0.3) — 10-Q Summary - TradingView
VERU: PLATEAU trial fully enrolled; cash supports operations past interim data; key patent secured - TradingView
VERU: Net loss narrowed, cash increased, but going concern risk remains amid clinical trial progress - TradingView
Q3 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239 - Quiver Quantitative
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingView
Veru completes enrollment of obesity drug trial with 239 patients - Investing.com
Veru Q3 Results: EPS beats estimates, losses narrow 40% YoY - scanx.trade
Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline - Quiver Quantitative
Veru completes enrollment of obesity drug trial with 239 patients By Investing.com - Investing.com UK
VERU: PLATEAU trial fully enrolled; Q3 net loss narrows and patent protection extended to 2044 - TradingView
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - Yahoo Finance
Veru Inc (VERU) Stock News Today - tradingkey.com
VERU Q3 2026 Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More - Moomoo
Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Veru Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
VERU Q3'26 Earnings: EPS estimate is (0.32) USD - TradingView
Veru receives patent allowance for enobosarm combination therapy - Investing.com
Veru receives patent allowance for enobosarm combination therapy By Investing.com - Investing.com Canada
VeruInterim Analysis Results Expected Q1 2 - Moomoo
Veru Announces Notice of Allowance for Key Me - Moomoo
Veru receives US patent allowance for enobosarm with semaglutide for quality weight loss until 2044 - pluang.com
Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update - Quiver Quantitative
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th - The Manila Times
Veru to report Q3 fiscal 2026 results on August 10, highlighting obesity drug trial progress. - pluang.com
Veru Inc. (VERU) Edges Higher: Stock Climbs 0.90% to $2.24Pairs Trade - dars.gov.et
Veru Inc (VERU) Institutional Confidence - tradingkey.com
Veru Inc (NASDAQ: VERU) Share Price, VERU Stock News, VERU Share Price & Updates - Kalkine
Veru Inc. (VERU) Holds Steady Near Support as Biotech Sector Remains CautiousOBV Divergence - dars.gov.et
VERU Q3'26 Earnings: revenue estimate is 0 USD - TradingView
VERU Completes Enrollment in Phase 2b PLATEAU Study - GuruFocus
Veru Inc (VERU) Cash Flow - TradingKey
Veru completes enrollment in obesity drug trial with 200 patients - Investing.com
Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity - Quiver Quantitative
Veru Inc (VERU) Valuation: PE, PB & Fair Value Analysis - TradingKey
VERU|Veru Inc|Price:2.280|Chg%:+0.030 - TradingKey
Veru Inc. completes Phase 2b PLATEAU trial enrollment for obesity drug - scanx.trade
Veru Inc (VERU) Earnings Date & Reports & Earnings News - tradingkey.com
Veru Inc. Revenue Breakdown – NASDAQ:VERU - TradingView
Veru Inc (VERU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VERU|Veru Inc|Price:2.250|Chg%:-0.060 - TradingKey
Veru Inc (VERU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Veru Inc (VERU) Balance Sheet - TradingKey
TradingKey - TradingKey
Veru Inc (VERU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veru Inc. (VERU) Slips 2.6% as Stock Tests Key Support LevelsFlat Correction - dars.gov.et
Veru Inc (VERU) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):